These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
||||
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
||||
|
|
|
|||||||
| (State of incorporation) | (I.R.S. Employer Identification No.) | |||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
|
|
|
|
||||||
|
|
☒
|
Accelerated filer |
☐
|
||||||||
| Non-accelerated filer |
☐
|
Smaller reporting company |
|
||||||||
| Emerging growth company |
|
||||||||||
| 9/30/2023 | 12/31/2022 | |||||||||||||
| ASSETS | ||||||||||||||
| Cash and cash equivalents | $ |
|
$ |
|
||||||||||
| Accounts receivable and accrued revenue |
|
|
||||||||||||
| Investments |
|
|
||||||||||||
|
Assets of consolidated sponsored investment products ($
|
|
|
||||||||||||
| Operating lease assets |
|
|
||||||||||||
| Property, equipment and software, net |
|
|
||||||||||||
| Intangible assets, net |
|
|
||||||||||||
| Goodwill |
|
|
||||||||||||
| Other assets |
|
|
||||||||||||
| Total assets | $ |
|
$ |
|
||||||||||
| LIABILITIES | ||||||||||||||
| Accounts payable and accrued expenses | $ |
|
$ |
|
||||||||||
|
Liabilities of consolidated sponsored investment products ($
|
|
|
||||||||||||
| Operating lease liabilities |
|
|
||||||||||||
| Accrued compensation and related costs |
|
|
||||||||||||
| Supplemental savings plan liability |
|
|
||||||||||||
| Contingent consideration liability |
|
|
||||||||||||
| Income taxes payable |
|
|
||||||||||||
| Total liabilities |
|
|
||||||||||||
| Commitments and contingent liabilities |
|
|
||||||||||||
| Redeemable non-controlling interests |
|
|
||||||||||||
| STOCKHOLDERS’ EQUITY | ||||||||||||||
|
Preferred stock, undesignated, $
|
|
|
||||||||||||
|
Common stock, $
|
|
|
||||||||||||
| Additional capital in excess of par value |
|
|
||||||||||||
| Retained earnings |
|
|
||||||||||||
| Accumulated other comprehensive loss |
(
|
(
|
||||||||||||
| Total stockholders’ equity attributable to T. Rowe Price Group, Inc. |
|
|
||||||||||||
| Non-controlling interests in consolidated entities |
|
|
||||||||||||
| Total stockholders’ equity |
|
|
||||||||||||
| Total liabilities, redeemable non-controlling interests, and stockholders’ equity | $ |
|
$ |
|
||||||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||
| 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | ||||||||||||||||||||
| Revenues | |||||||||||||||||||||||
| Investment advisory fees | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Capital allocation-based income |
|
|
|
(
|
|||||||||||||||||||
| Administrative, distribution, and servicing fees |
|
|
|
|
|||||||||||||||||||
| Net revenues |
|
|
|
|
|||||||||||||||||||
| Operating expenses | |||||||||||||||||||||||
| Compensation and related costs |
|
|
|
|
|||||||||||||||||||
| Distribution and servicing |
|
|
|
|
|||||||||||||||||||
| Advertising and promotion |
|
|
|
|
|||||||||||||||||||
| Product and recordkeeping related costs |
|
|
|
|
|||||||||||||||||||
| Technology, occupancy, and facility costs |
|
|
|
|
|||||||||||||||||||
| General, administrative, and other |
|
|
|
|
|||||||||||||||||||
| Change in fair value of contingent consideration |
|
(
|
(
|
(
|
|||||||||||||||||||
| Acquisition-related amortization and impairment costs |
|
|
|
|
|||||||||||||||||||
| Total operating expenses |
|
|
|
|
|||||||||||||||||||
| Net operating income |
|
|
|
|
|||||||||||||||||||
| Non-operating income (loss) | |||||||||||||||||||||||
| Net gains (losses) on investments |
|
(
|
|
(
|
|||||||||||||||||||
| Net gains (losses) on consolidated investment products |
(
|
(
|
|
(
|
|||||||||||||||||||
| Other losses |
(
|
|
(
|
(
|
|||||||||||||||||||
| Total non-operating income (loss) |
|
(
|
|
(
|
|||||||||||||||||||
| Income before income taxes |
|
|
|
|
|||||||||||||||||||
| Provision for income taxes |
|
|
|
|
|||||||||||||||||||
| Net income |
|
|
|
|
|||||||||||||||||||
|
Less: net income (loss) attributable to redeemable
non-controlling interests |
(
|
(
|
|
(
|
|||||||||||||||||||
| Net income attributable to T. Rowe Price Group | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Earnings per share on common stock of T. Rowe Price Group | |||||||||||||||||||||||
| Basic | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Diluted | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||
| 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | ||||||||||||||||||||
| Net income | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Other comprehensive income (loss) | |||||||||||||||||||||||
| Currency translation adjustments | |||||||||||||||||||||||
| Consolidated T. Rowe Price investment products - variable interest entities |
(
|
(
|
|
(
|
|||||||||||||||||||
| Reclassification (gains) losses recognized in non-operating income upon deconsolidation of certain T. Rowe Price investment products |
(
|
|
(
|
(
|
|||||||||||||||||||
|
Total currency translation adjustments of consolidated T. Rowe Price investment products - variable interest entities
|
(
|
(
|
|
(
|
|||||||||||||||||||
|
Equity method investments
|
|
|
|
(
|
|||||||||||||||||||
| Other comprehensive income (loss) before income taxes |
(
|
(
|
|
(
|
|||||||||||||||||||
| Net deferred tax (expense) benefits |
|
|
(
|
|
|||||||||||||||||||
| Total other comprehensive income (loss) |
(
|
(
|
|
(
|
|||||||||||||||||||
| Total comprehensive income |
|
|
|
|
|||||||||||||||||||
| Less: comprehensive income (loss) attributable to redeemable non-controlling interests |
(
|
(
|
|
(
|
|||||||||||||||||||
| Total comprehensive income attributable to T. Rowe Price Group | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Nine months ended | |||||||||||
| 9/30/2023 | 9/30/2022 | ||||||||||
| Cash flows from operating activities | |||||||||||
| Net income | $ |
|
$ |
|
|||||||
| Adjustments to reconcile net income to net cash provided by operating activities | |||||||||||
| Depreciation, amortization and impairment of property, equipment and software |
|
|
|||||||||
| Amortization and impairment of acquisition-related assets and retention arrangements |
|
|
|||||||||
| Fair value remeasurement of contingent consideration liability |
(
|
(
|
|||||||||
|
Stock-based compensation expense
|
|
|
|||||||||
| Net (gains) losses recognized on investments |
(
|
|
|||||||||
| Net redemptions in sponsored investment products used to economically hedge supplemental savings plan liability |
|
|
|||||||||
| Net change in securities held by consolidated sponsored investment products |
(
|
|
|||||||||
| Other changes in assets and liabilities |
|
|
|||||||||
| Net cash provided by operating activities |
|
|
|||||||||
| Cash flows from investing activities | |||||||||||
| Purchases of sponsored investment products |
(
|
(
|
|||||||||
| Dispositions of sponsored investment products |
|
|
|||||||||
| Net cash of sponsored investment products on deconsolidation |
(
|
(
|
|||||||||
| Additions to property, equipment and software |
(
|
(
|
|||||||||
| Other investing activity |
(
|
|
|||||||||
| Net cash provided by (used in) investing activities |
|
(
|
|||||||||
| Cash flows from financing activities | |||||||||||
| Repurchases of common stock |
(
|
(
|
|||||||||
| Common share issuances under stock-based compensation plans |
|
|
|||||||||
| Dividends paid to common stockholders of T. Rowe Price |
(
|
(
|
|||||||||
| Net distributions to non-controlling interests in consolidated entities |
(
|
(
|
|||||||||
| Net subscriptions (redemptions) from redeemable non-controlling interest holders |
|
(
|
|||||||||
| Net cash used in financing activities |
(
|
(
|
|||||||||
|
Effect of exchange rate changes on cash and cash equivalents of consolidated
T. Rowe Price investment products
|
(
|
|
|||||||||
| Net change in cash and cash equivalents during period |
|
|
|||||||||
|
Cash and cash equivalents at beginning of period, including $
|
|
|
|||||||||
|
Cash and cash equivalents at end of period, including $
|
$ |
|
$ |
|
|||||||
|
Three months ended 9/30/2023
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Common
shares outstanding |
Common
stock |
Additional
capital in excess of par value |
Retained
earnings |
AOCI
(1)
|
Total
stockholders’ equity attributable to T. Rowe Price Group, Inc. |
Non-controlling interests in consolidated entities | Total stockholders’ equity |
Redeemable non-controlling interests
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Balances at June 30, 2023
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||
| Net income | — | — | — |
|
— |
|
|
|
(
|
||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | — | — | — | — |
|
|
— |
|
(
|
||||||||||||||||||||||||||||||||||||||||||||
|
Dividends declared ($
|
— | — | — |
(
|
— |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Shares issued upon option exercises |
|
|
|
— | — |
|
— |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Restricted shares issued, net of shares withheld for taxes |
|
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Net shares issued upon vesting of restricted stock units |
|
— |
(
|
— | — |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — |
|
— | — |
|
— |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Restricted stock units issued as dividend equivalents | — | — |
|
(
|
— | — | — |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Common shares repurchased |
(
|
(
|
(
|
— | — |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Net distributions to non-controlling interests in consolidated entities | — | — | — | — | — | — |
(
|
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Net subscriptions into T. Rowe Price investment products | — | — | — | — | — | — | — | — |
|
||||||||||||||||||||||||||||||||||||||||||||
| Net deconsolidations of T. Rowe Price investment products | — | — | — | — | — | — | — | — |
(
|
||||||||||||||||||||||||||||||||||||||||||||
|
Balances at September 30, 2023
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||
|
Three months ended 9/30/2022
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Common
shares outstanding |
Common
stock |
Additional
capital in excess of par value |
Retained
earnings |
AOCI
(1)
|
Total
stockholders’ equity attributable to T. Rowe Price Group, Inc. |
Non-controlling interests in consolidated entities | Total stockholders’ equity | Redeemable non-controlling interests | |||||||||||||||||||||||||||||||||||||||||||||
|
Balances at June 30, 2022
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||
| Net income (loss) | — | — | — |
|
— |
|
|
|
(
|
||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive loss, net of tax | — | — | — | — |
(
|
(
|
— |
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||
|
Dividends declared ($
|
— | — | — |
(
|
— |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Shares issued upon option exercises |
|
— |
|
— | — |
|
— |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Net shares issued upon vesting of restricted stock units |
|
— |
(
|
— | — |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — |
|
— | — |
|
— |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Common shares repurchased |
(
|
(
|
(
|
— | — |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Net distributions from non-controlling interests in consolidated entities | — | — | — | — | — | — |
(
|
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Net subscriptions into T. Rowe Price investment products | — | — | — | — | — | — | — | — |
|
||||||||||||||||||||||||||||||||||||||||||||
| Net consolidations of T. Rowe Price investment products | — | — | — | — | — | — | — | — |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Balances at September 30, 2022
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||
|
Nine months ended 9/30/2023
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Common
shares outstanding |
Common
stock |
Additional
capital in excess of par value |
Retained
earnings |
AOCI
(1)
|
Total
stockholders’ equity attributable to T. Rowe Price Group, Inc. |
Non-controlling interests in consolidated entities | Total Stockholders’ equity | Redeemable non-controlling interests | |||||||||||||||||||||||||||||||||||||||||||||
|
Balances at December 31, 2022
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||
| Net income | — | — | — |
|
— |
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income, net of tax | — | — | — | — |
|
|
— |
|
|
||||||||||||||||||||||||||||||||||||||||||||
|
Dividends declared ($
|
— | — | — |
(
|
— |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Shares issued upon option exercises |
|
|
|
— | — |
|
— |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Restricted shares issued, net of shares withheld for taxes |
|
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||
| Net shares issued upon vesting of restricted stock units |
|
— |
(
|
— | — |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — |
|
— | — |
|
— |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Restricted stock units issued as dividend equivalents | — | — |
|
(
|
— | — | — |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Common shares repurchased |
(
|
(
|
(
|
— |
(
|
— |
(
|
— | |||||||||||||||||||||||||||||||||||||||||||||
| Net distributions to non-controlling interests in consolidated entities | — | — | — | — | — | — |
(
|
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Net subscriptions into T. Rowe Price investment products | — | — | — | — | — | — | — | — |
|
||||||||||||||||||||||||||||||||||||||||||||
| Net deconsolidations of T. Rowe Price investment products | — | — | — | — | — | — | — | — |
(
|
||||||||||||||||||||||||||||||||||||||||||||
|
Balances at September 30, 2023
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||
| Nine months ended 9/30/2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Common
shares outstanding |
Common
stock |
Additional
capital in excess of par value |
Retained
earnings |
AOCI
(1)
|
Total
stockholders’ equity attributable to T. Rowe Price Group, Inc. |
Non-controlling interests in consolidated entities | Total Stockholders’ equity | Redeemable non-controlling interests | |||||||||||||||||||||||||||||||||||||||||||||
|
Balances at December 31, 2021
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||
| Net income | — | — | — |
|
— |
|
(
|
|
(
|
||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income (loss), net of tax | — | — | — | — |
(
|
(
|
— |
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||
|
Dividends declared ($
|
— | — | — |
(
|
— |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Shares issued upon option exercises |
|
|
|
— | — |
|
— |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Net shares issued upon vesting of restricted stock units |
|
— |
(
|
— | — |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — |
|
— | — |
|
— |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Restricted stock units issued as dividend equivalents |
|
— |
|
(
|
— | — | — |
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Common shares repurchased |
(
|
(
|
(
|
(
|
— |
(
|
— |
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Net distributions to non-controlling interests in consolidated entities | — | — | — | — | — | — |
(
|
(
|
— | ||||||||||||||||||||||||||||||||||||||||||||
| Net redemptions from T. Rowe Price investment products | — | — | — | — | — | — | — | — |
(
|
||||||||||||||||||||||||||||||||||||||||||||
| Net deconsolidations of T. Rowe Price investment products | — | — | — | — | — | — | — | — |
(
|
||||||||||||||||||||||||||||||||||||||||||||
|
Balances at September 30, 2022
|
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investment advisory fees | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed income, including money market |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Multi-asset |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternatives |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total investment advisory fees | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capital allocation-based income |
|
|
|
(
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total administrative, distribution, and servicing fees |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net revenues | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Average AUM
(in billions)
:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed income, including money market |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Multi-asset |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Alternatives |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average AUM | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 9/30/2023 | 12/31/2022 | |||||||||
| Investments held at fair value | |||||||||||
| T. Rowe Price investment products | |||||||||||
| Discretionary investments | $ |
|
$ |
|
|||||||
| Seed capital |
|
|
|||||||||
| Supplemental savings plan liability economic hedges |
|
|
|||||||||
| Investment partnerships and other investments |
|
|
|||||||||
| Investments in affiliated collateralized loan obligations |
|
|
|||||||||
| Equity method investments | |||||||||||
| T. Rowe Price investment products | |||||||||||
| Discretionary investments |
|
|
|||||||||
| Seed capital |
|
|
|||||||||
| Supplemental savings plan liability economic hedges |
|
|
|||||||||
|
|
|
|
|||||||||
| Investments in affiliated private investment funds - carried interest |
|
|
|||||||||
| Investments in affiliated private investment funds - seed/co-investment |
|
|
|||||||||
| Other investment partnerships and investments |
|
|
|||||||||
| Held to maturity | |||||||||||
| Investments in affiliated collateralized loan obligations |
|
|
|||||||||
| Certificates of deposit |
|
|
|||||||||
| U.S. Treasury note |
|
|
|||||||||
| Total | $ |
|
$ |
|
|||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | |||||||||||||||||||
| Net increase (decrease) in assets of consolidated sponsored investment products | $ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Net increase (decrease) in liabilities of consolidated sponsored investment products | $ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Net increase (decrease) in redeemable non-controlling interests | $ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||
| Gains recognized upon deconsolidation | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| (in millions) | 9/30/2023 | 12/31/2022 | |||||||||
| Investment carrying values | $ |
|
$ |
|
|||||||
| Unfunded capital commitments |
|
|
|||||||||
| Accounts receivable |
|
|
|||||||||
| $ |
|
$ |
|
||||||||
| (in millions) | 9/30/2023 | 12/31/2022 | ||||||||||||
| Assets | $ |
|
$ |
|
||||||||||
| Liabilities | $ |
|
$ |
|
||||||||||
| Non-controlling interest | $ |
|
$ |
|
||||||||||
| 9/30/2023 | 12/31/2022 | ||||||||||||||||||||||||||||||||||
| (in millions) |
Level 1
|
Level 2
|
Level 3 |
Level 1
|
Level 2
|
Level 3 | |||||||||||||||||||||||||||||
| T. Rowe Price investment products | |||||||||||||||||||||||||||||||||||
| Cash equivalents held in money market funds | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| Discretionary investments |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Seed capital |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Supplemental savings plan liability economic hedges |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Other investments |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Investments in affiliated collateralized loan obligations |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| Contingent consideration liability | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| Contingent Consideration Liability | |||||||||||||||||||||||
|
Three months ended
|
Nine months ended
|
||||||||||||||||||||||
| (in millions) | 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | |||||||||||||||||||
| Balance at beginning of period | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Measurement period adjustment |
|
|
|
(
|
|||||||||||||||||||
| Unrealized gains, included in earnings |
|
(
|
(
|
(
|
|||||||||||||||||||
| Balance at end of period | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| 9/30/2023 | 12/31/2022 | ||||||||||||||||||||||||||||||||||
|
(in millions)
|
Voting
interest entities |
Variable interest entities
|
Total
|
Voting
interest entities |
Variable interest entities
|
Total
|
|||||||||||||||||||||||||||||
|
Cash and cash equivalents
(1)
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
|
Investments
(2)
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Other assets |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Total assets |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Liabilities |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Net assets | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| Attributable to T. Rowe Price Group | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| Attributable to redeemable non-controlling interests |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||
| Three months ended | |||||||||||||||||||||||||||||||||||
| 9/30/2023 | 9/30/2022 | ||||||||||||||||||||||||||||||||||
| (in millions) |
Voting
interest entities |
Variable interest entities
|
Total
|
Voting
interest entities |
Variable interest entities
|
Total
|
|||||||||||||||||||||||||||||
| Operating expenses reflected in net operating income | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| Net investment income (loss) reflected in non-operating income (loss) |
(
|
(
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||
| Impact on income before taxes | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| Net income (loss) attributable to T. Rowe Price Group | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| Net income (loss) attributable to redeemable non-controlling interests |
(
|
(
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||
| $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||||
| Nine months ended | |||||||||||||||||||||||||||||||||||
| 9/30/2023 | 9/30/2022 | ||||||||||||||||||||||||||||||||||
| (in millions) |
Voting
interest entities |
Variable interest entities | Total |
Voting
interest entities |
Variable interest entities | Total | |||||||||||||||||||||||||||||
| Operating expenses reflected in net operating income | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| Net investment income (loss) reflected in non-operating income (loss) |
|
|
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||
| Impact on income before taxes | $ |
(
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| Net income (loss) attributable to T. Rowe Price Group | $ |
(
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||
| Net income (loss) attributable to redeemable non-controlling interests |
(
|
|
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||
| $ |
(
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||||
| Nine months ended | |||||||||||||||||||||||||||||||||||
| 9/30/2023 | 9/30/2022 | ||||||||||||||||||||||||||||||||||
|
(in millions)
|
Voting
interest entities |
Variable interest entities
|
Total
|
Voting
interest entities |
Variable interest entities
|
Total
|
|||||||||||||||||||||||||||||
| Net cash provided by (used in) operating activities | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||||||||||
| Net cash used in investing activities |
(
|
(
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||
| Net cash provided by (used in) financing activities |
|
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||
| Effect of exchange rate changes on cash and cash equivalents of consolidated sponsored investment products |
|
(
|
(
|
|
|
|
|||||||||||||||||||||||||||||
|
Net change in cash and cash equivalents during period
|
|
(
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||
|
Cash and cash equivalents at beginning of year
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||
|
Cash and cash equivalents at end of period
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||
| 9/30/2023 | 12/31/2022 | ||||||||||||||||||||||||||||||||||||||||||||||
|
(in millions)
|
Level 1
|
Level 2
|
Level 3 |
Level 1
|
Level 2
|
Level 3 | |||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||
| Cash equivalents | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||
| Equity securities |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||
| Fixed income securities |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||
| Other investments |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||
| $ |
|
$ |
|
$ |
|
$ | — | $ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||
| Liabilities | $ |
(
|
$ |
(
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||||||||||
| (in millions) | 9/30/2023 | 12/31/2022 | |||||||||
| Goodwill | $ |
|
$ |
|
|||||||
| Indefinite-lived intangible assets - trade name |
|
|
|||||||||
| Indefinite-lived intangible assets - investment advisory agreements |
|
|
|||||||||
| Definite-lived intangible assets - investment advisory agreements |
|
|
|||||||||
| Total | $ |
|
$ |
|
|||||||
| Options |
Weighted-
average
exercise
price
|
||||||||||
|
Outstanding at December 31, 2022
|
|
$ |
|
||||||||
| Exercised |
(
|
$ |
|
||||||||
|
Outstanding at September 30, 2023
|
|
$ |
|
||||||||
|
Exercisable at September 30, 2023
|
|
$ |
|
||||||||
|
Restricted
shares
|
Restricted
stock
units
|
Weighted-average
fair value
|
|||||||||||||||
|
Nonvested at December 31, 2022
|
|
|
$ |
|
|||||||||||||
| Time-based grants |
|
|
$ |
|
|||||||||||||
| Dividend equivalents granted to non-employee directors |
|
|
$ |
|
|||||||||||||
| Vested |
(
|
(
|
$ |
|
|||||||||||||
| Forfeited |
|
(
|
$ |
|
|||||||||||||
|
Nonvested at September 30, 2023
|
|
|
$ |
|
|||||||||||||
| (in millions) | |||||
| Fourth quarter 2023 | $ |
|
|||
| 2024 |
|
||||
| 2025 through 2029 |
|
||||
| Total | $ |
|
|||
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | |||||||||||||||||||
| Net income attributable to T. Rowe Price | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Less: net income allocated to outstanding restricted stock and stock unit holders |
|
|
|
|
|||||||||||||||||||
| Net income allocated to common stockholders | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Weighted-average common shares | |||||||||||||||||||||||
| Outstanding |
|
|
|
|
|||||||||||||||||||
| Outstanding assuming dilution |
|
|
|
|
|||||||||||||||||||
|
Three months ended 9/30/2023
|
Three months ended 9/30/2022
|
|||||||||||||||||||||||||||||||||||||
| (in millions) | Equity method investments | Consolidated T. Rowe Price investment products - variable interest entities |
Total currency translation adjustments
|
Equity method investments | Consolidated T. Rowe Price investment products - variable interest entities | Total currency translation adjustments | ||||||||||||||||||||||||||||||||
| Balances at beginning of period | $ |
(
|
$ |
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||||||
|
Other comprehensive income (loss) before reclassifications and income taxes
|
|
(
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
|
Reclassification adjustments recognized in non-operating income
|
|
(
|
(
|
|
|
|
||||||||||||||||||||||||||||||||
|
|
(
|
|
|
(
|
(
|
|||||||||||||||||||||||||||||||||
|
Net deferred tax benefits (income taxes)
|
(
|
|
|
(
|
|
|
||||||||||||||||||||||||||||||||
|
Other comprehensive income (loss)
|
|
(
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Balances at end of period | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||||||
|
Nine months ended 9/30/2023
|
Nine months ended 9/30/2022 | |||||||||||||||||||||||||||||||||||||
| (in millions) | Equity method investments | Consolidated T. Rowe Price investment products - variable interest entities | Total currency translation adjustments |
Equity method investments
|
Consolidated T. Rowe Price investment products - variable interest entities | Total currency translation adjustments | ||||||||||||||||||||||||||||||||
| Balances at beginning of period | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
(
|
||||||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications and income taxes |
|
|
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Reclassification adjustments recognized in non-operating income |
|
(
|
(
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
|
|
(
|
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||||||
| Net deferred tax benefits (income taxes) |
(
|
|
(
|
(
|
|
|
||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) |
|
(
|
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Balances at end of period | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||||||
| Three months ended | Nine months ended | |||||||||||||
| Index | 9/30/2023 | 9/30/2023 | ||||||||||||
| S&P 500 Index | (3.3)% | 13.1% | ||||||||||||
|
NASDAQ Composite Index
(1)
|
(4.1)% | 26.3% | ||||||||||||
| Russell 2000 Index | (5.1)% | 2.5% | ||||||||||||
| MSCI EAFE (Europe, Australasia, and Far East) Index | (4.1)% | 7.6% | ||||||||||||
| MSCI Emerging Markets Index | (2.8)% | 2.2% | ||||||||||||
| Three months ended | Nine months ended | |||||||||||||
| Index | 9/30/2023 | 9/30/2023 | ||||||||||||
| Bloomberg U.S. Aggregate Bond Index | (3.2)% | (1.2)% | ||||||||||||
| JPMorgan Global High Yield Index | 0.8% | 6.2% | ||||||||||||
| Bloomberg Municipal Bond Index | (4.0)% | (1.4)% | ||||||||||||
| Bloomberg Global Aggregate Ex-U.S. Dollar Bond Index | (4.0)% | (3.2)% | ||||||||||||
| JPMorgan Emerging Markets Bond Index Plus | (3.4)% | (0.2)% | ||||||||||||
| ICE Bank of America U.S. High Yield Index | 0.5% | 6.0% | ||||||||||||
| Credit Suisse Leveraged Loan Index | 3.4% | 9.9% | ||||||||||||
|
Three months ended 9/30/2023
|
Nine months ended 9/30/2023
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (in billions) | Equity | Fixed income, including money market |
Multi-asset
(2)
|
Alternatives
(3)
|
Total | Equity | Fixed income, including money market |
Multi-asset
(2)
|
Alternatives
(3)
|
Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets under management at beginning of period | $ | 732.2 | $ | 169.3 | $ | 453.2 | $ | 44.7 | $ | 1,399.4 | $ | 664.2 | $ | 167.0 | $ | 400.1 | $ | 43.4 | $ | 1,274.7 | ||||||||||||||||||||||||||||||||||||||||||
|
Net cash flows
(4)
|
(19.7) | 1.0 | 0.4 | 0.9 | (17.4) | (62.7) | (0.8) | 9.1 | 0.9 | (53.5) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Net market appreciation (depreciation) and gains(losses
(5)
|
(22.5) | (1.0) | (13.1) | 1.1 | (35.5) | 88.5 | 3.1 | 31.3 | 2.4 | 125.3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Change during the period | (42.2) | — | (12.7) | 2.0 | (52.9) | 25.8 | 2.3 | 40.4 | 3.3 | 71.8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets under management at September 30, 2023 | $ | 690.0 | $ | 169.3 | $ | 440.5 | $ | 46.7 | $ | 1,346.5 | $ | 690.0 | $ | 169.3 | $ | 440.5 | $ | 46.7 | $ | 1,346.5 | ||||||||||||||||||||||||||||||||||||||||||
|
% of U.S. mutual funds that outperformed Morningstar median
(2),(3)
|
||||||||||||||||||||||||||
| 1 year | 3 years | 5 years | 10 years | |||||||||||||||||||||||
| Equity | 49% | 50% | 70% | 73% | ||||||||||||||||||||||
| Fixed Income | 60% | 59% | 73% | 68% | ||||||||||||||||||||||
| Multi-Asset | 73% | 58% | 86% | 88% | ||||||||||||||||||||||
| All Funds | 61% | 55% | 76% | 75% | ||||||||||||||||||||||
|
% of U.S. mutual funds that outperformed passive peer median
(2),(4)
|
||||||||||||||||||||||||||
| 1 year | 3 years | 5 years | 10 years | |||||||||||||||||||||||
| Equity | 49% | 36% | 53% | 56% | ||||||||||||||||||||||
| Fixed Income | 47% | 53% | 57% | 57% | ||||||||||||||||||||||
| Multi-Asset | 76% | 63% | 90% | 60% | ||||||||||||||||||||||
| All Funds | 59% | 49% | 65% | 57% | ||||||||||||||||||||||
|
% of composites that outperformed benchmarks
(5)
|
||||||||||||||||||||||||||
| 1 year | 3 years | 5 years | 10 years | |||||||||||||||||||||||
| Equity | 35% | 33% | 56% | 66% | ||||||||||||||||||||||
| Fixed Income | 49% | 51% | 51% | 74% | ||||||||||||||||||||||
| All Composites | 41% | 40% | 54% | 69% | ||||||||||||||||||||||
| AUM Weighted Performance | ||||||||||||||||||||||||||
|
% of U.S. mutual funds AUM that outperformed Morningstar median
(2),(3)
|
||||||||||||||||||||||||||
| 1 year | 3 years | 5 years | 10 years | |||||||||||||||||||||||
| Equity | 64% | 47% | 70% | 83% | ||||||||||||||||||||||
| Fixed Income | 55% | 68% | 90% | 81% | ||||||||||||||||||||||
| Multi-Asset | 93% | 89% | 96% | 87% | ||||||||||||||||||||||
| All Funds | 71% | 60% | 79% | 86% | ||||||||||||||||||||||
|
% of U.S. mutual funds AUM that outperformed passive peer median
(2),(4)
|
||||||||||||||||||||||||||
| 1 year | 3 years | 5 years | 10 years | |||||||||||||||||||||||
| Equity | 65% | 26% | 51% | 52% | ||||||||||||||||||||||
| Fixed Income | 49% | 71% | 73% | 68% | ||||||||||||||||||||||
| Multi-Asset | 96% | 92% | 97% | 95% | ||||||||||||||||||||||
| All Funds | 73% | 49% | 66% | 65% | ||||||||||||||||||||||
|
% of composites AUM that outperformed benchmarks
(5)
|
||||||||||||||||||||||||||
| 1 year | 3 years | 5 years | 10 years | |||||||||||||||||||||||
| Equity | 44% | 34% | 46% | 52% | ||||||||||||||||||||||
| Fixed Income | 52% | 51% | 51% | 66% | ||||||||||||||||||||||
| All Composites | 46% | 37% | 47% | 54% | ||||||||||||||||||||||
| Three months ended | Q3 2023 vs. Q3 2022 | Nine months ended | YTD 2023 vs. YTD 2022 | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions, except per-share data) | 9/30/2023 | 9/30/2022 | $ change |
% change
(1)
|
9/30/2023 | 9/30/2022 | $ change |
% change
(1)
|
||||||||||||||||||||||||||||||||||||||||||
| U.S. GAAP basis | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Investment advisory fees | $ | 1,463.9 | $ | 1,442.0 | $ | 21.9 | 1.5 | % | $ | 4,286.5 | $ | 4,600.8 | $ | (314.3) | (6.8) | % | ||||||||||||||||||||||||||||||||||
|
Capital allocation-based income
(2)
|
$ | 66.1 | $ | 1.1 | $ | 65.0 | n/m | $ | 121.7 | $ | (80.8) | $ | 202.5 | n/m | ||||||||||||||||||||||||||||||||||||
| Net revenues | $ | 1,670.7 | $ | 1,588.2 | $ | 82.5 | 5.2 | % | $ | 4,818.5 | $ | 4,964.2 | $ | (145.7) | (2.9) | % | ||||||||||||||||||||||||||||||||||
| Operating expenses | $ | 1,089.4 | $ | 1,013.6 | $ | 75.8 | 7.5 | % | $ | 3,219.5 | $ | 2,843.6 | $ | 375.9 | 13.2 | % | ||||||||||||||||||||||||||||||||||
| Net operating income | $ | 581.3 | $ | 574.6 | $ | 6.7 | 1.2 | % | $ | 1,599.0 | $ | 2,120.6 | $ | (521.6) | (24.6) | % | ||||||||||||||||||||||||||||||||||
| Non-operating income (loss) | $ | 2.8 | $ | (82.8) | $ | 85.6 | n/m | $ | 244.4 | $ | (561.2) | $ | 805.6 | n/m | ||||||||||||||||||||||||||||||||||||
| Net income attributable to T. Rowe Price | $ | 453.2 | $ | 384.4 | $ | 68.8 | 17.9 | % | $ | 1,351.1 | $ | 1,291.9 | $ | 59.2 | 4.6 | % | ||||||||||||||||||||||||||||||||||
| Diluted earnings per common share | $ | 1.97 | $ | 1.66 | $ | 0.31 | 18.7 | % | $ | 5.86 | $ | 5.54 | $ | 0.32 | 5.8 | % | ||||||||||||||||||||||||||||||||||
| Weighted average common shares outstanding assuming dilution | 224.8 | 226.3 | $ | (1.5) | (0.7) | % | 225.1 | 228.0 | $ | (2.9) | (1.3) | % | ||||||||||||||||||||||||||||||||||||||
|
Adjusted non-GAAP basis
(3)
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Operating expenses | $ | 1,061.3 | $ | 1,028.2 | $ | 33.1 | 3.2 | % | $ | 3,110.0 | $ | 3,014.6 | $ | 95.4 | 3.2 | % | ||||||||||||||||||||||||||||||||||
| Net operating income | $ | 635.9 | $ | 573.7 | $ | 62.2 | 10.8 | % | $ | 1,760.5 | $ | 1,991.4 | $ | (230.9) | (11.6) | % | ||||||||||||||||||||||||||||||||||
| Non-operating income (loss) | $ | 28.7 | $ | (3.7) | $ | 32.4 | n/m | $ | 91.3 | $ | (58.1) | $ | 149.4 | n/m | ||||||||||||||||||||||||||||||||||||
| Net income attributable to T. Rowe Price | $ | 499.5 | $ | 430.6 | $ | 68.9 | 16.0 | % | $ | 1,355.4 | $ | 1,465.2 | $ | (109.8) | (7.5) | % | ||||||||||||||||||||||||||||||||||
| Diluted earnings per common share | $ | 2.17 | $ | 1.86 | $ | 0.31 | 16.7 | % | $ | 5.88 | $ | 6.28 | $ | (0.40) | (6.4) | % | ||||||||||||||||||||||||||||||||||
|
Assets under management
(in billions)
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Average assets under management
|
$ | 1,393.6 | $ | 1,347.5 | $ | 46.1 | 3.4 | % | $ | 1,358.2 | $ | 1,437.1 | $ | (78.9) | (5.5) | % | ||||||||||||||||||||||||||||||||||
| Ending assets under management | $ | 1,346.5 | $ | 1,230.0 | $ | 116.5 | 9.5 | % | $ | 1,346.5 | $ | 1,230.0 | $ | 116.5 | 9.5 | % | ||||||||||||||||||||||||||||||||||
| Three months ended | Q3 2023 vs. Q3 2022 | Nine months ended | YTD 2023 vs. YTD 2022 | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 9/30/2023 | 9/30/2022 | $ change | % change | 9/30/2023 | 9/30/2022 | $ change | % change | ||||||||||||||||||||||||||||||||||||||||||
| Investment advisory fees | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity | $ | 885.0 | $ | 897.0 | $ | (12.0) | (1.3) | % | $ | 2,581.2 | $ | 2,924.0 | $ | (342.8) | (11.7) | % | ||||||||||||||||||||||||||||||||||
| Fixed income | 100.9 | 107.6 | (6.7) | (6.2) | % | 303.3 | 324.1 | (20.8) | (6.4) | % | ||||||||||||||||||||||||||||||||||||||||
| Multi-asset | 405.5 | 367.2 | 38.3 | 10.4 | % | 1,182.8 | 1,149.3 | 33.5 | 2.9 | % | ||||||||||||||||||||||||||||||||||||||||
| Alternatives | 72.5 | 70.2 | 2.3 | 3.3 | % | 219.2 | 203.4 | 15.8 | 7.8 | % | ||||||||||||||||||||||||||||||||||||||||
| 1,463.9 | 1,442.0 | 21.9 | 1.5 | % | 4,286.5 | 4,600.8 | (314.3) | (6.8) | % | |||||||||||||||||||||||||||||||||||||||||
| Capital allocation-based income | 66.1 | 1.1 | 65.0 | n/m | 121.7 | (80.8) | 202.5 | n/m | ||||||||||||||||||||||||||||||||||||||||||
| Administrative, distribution, and servicing fees | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Administrative fees | 119.4 | 123.1 | (3.7) | (3.0) | % | 347.7 | 372.7 | (25.0) | (6.7) | % | ||||||||||||||||||||||||||||||||||||||||
| Distribution and servicing fees | $ | 21.3 | 22.0 | (0.7) | (3.2) | % | 62.6 | 71.5 | (8.9) | (12.4) | % | |||||||||||||||||||||||||||||||||||||||
| $ | 140.7 | 145.1 | (4.4) | (3.0) | % | 410.3 | 444.2 | (33.9) | (7.6) | % | ||||||||||||||||||||||||||||||||||||||||
| Net revenues | $ | 1,670.7 | $ | 1,588.2 | $ | 82.5 | 5.2 | % | $ | 4,818.5 | $ | 4,964.2 | $ | (145.7) | (2.9) | % | ||||||||||||||||||||||||||||||||||
|
Average assets under management
(in billions)
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity | $ | 725.0 | $ | 724.9 | $ | 0.1 | — | % | $ | 705.3 | $ | 793.0 | $ | (87.7) | (11.1) | % | ||||||||||||||||||||||||||||||||||
| Fixed income | 169.0 | 173.0 | (4.0) | (2.3) | % | 169.6 | 175.1 | (5.5) | (3.1) | % | ||||||||||||||||||||||||||||||||||||||||
| Multi-asset | 453.8 | 406.7 | 47.1 | 11.6 | % | 438.5 | 426.6 | 11.9 | 2.8 | % | ||||||||||||||||||||||||||||||||||||||||
| Alternatives | 45.8 | 42.9 | 2.9 | 6.8 | % | 44.8 | 42.4 | 2.4 | 5.7 | % | ||||||||||||||||||||||||||||||||||||||||
| Average assets under management | $ | 1,393.6 | $ | 1,347.5 | $ | 46.1 | 3.4 | % | $ | 1,358.2 | $ | 1,437.1 | $ | (78.9) | (5.5) | % | ||||||||||||||||||||||||||||||||||
|
Investment advisory annualized effective fee rate
(in bps) |
41.7 | 42.5 | (0.8) | (1.9) | % | 42.2 | 42.8 | (0.6) | (1.4) | % | ||||||||||||||||||||||||||||||||||||||||
| Three months ended | Q3 2023 vs. Q3 2022 | Nine months ended | YTD 2023 vs. YTD 2022 | |||||||||||||||||||||||||||||||||||||||||||||||
| (in millions) | 9/30/2023 | 9/30/2022 | $ change | % change | 9/30/2023 | 9/30/2022 | $ change | % change | ||||||||||||||||||||||||||||||||||||||||||
| Compensation, benefits and related costs | $ | 617.0 | $ | 595.6 | $ | 21.4 | 3.6 | % | $ | 1,801.3 | $ | 1,781.3 | $ | 20.0 | 1.1 | % | ||||||||||||||||||||||||||||||||||
| Acquisition-related retention agreements | 13.7 | 17.1 | (3.4) | (19.9) | % | 41.5 | 54.3 | (12.8) | (23.6) | % | ||||||||||||||||||||||||||||||||||||||||
| Capital allocation-based income compensation | 19.9 | 0.1 | 19.8 | n/m | 34.0 | (33.3) | 67.3 | n/m | ||||||||||||||||||||||||||||||||||||||||||
|
Supplemental savings plan
(1)
|
(14.2) | (24.7) | 10.5 | n/m | 61.3 | (169.2) | 230.5 | n/m | ||||||||||||||||||||||||||||||||||||||||||
| Total compensation and related costs | 636.4 | 588.1 | 48.3 | 8.2 | % | 1,938.1 | 1,633.1 | 305.0 | 18.7 | % | ||||||||||||||||||||||||||||||||||||||||
| Distribution and servicing | 74.9 | 69.9 | 5.0 | 7.2 | % | 214.2 | 231.5 | (17.3) | (7.5) | % | ||||||||||||||||||||||||||||||||||||||||
| Advertising and promotion | 21.1 | 24.3 | (3.2) | (13.2) | % | 69.8 | 69.1 | 0.7 | 1.0 | % | ||||||||||||||||||||||||||||||||||||||||
| Product and recordkeeping related costs | 73.1 | 75.6 | (2.5) | (3.3) | % | 222.9 | 232.3 | (9.4) | (4.0) | % | ||||||||||||||||||||||||||||||||||||||||
| Technology, occupancy, and facility costs | 159.7 | 143.6 | 16.1 | 11.2 | % | 461.0 | 411.8 | 49.2 | 11.9 | % | ||||||||||||||||||||||||||||||||||||||||
| General, administrative, and other | 85.7 | 114.9 | (29.2) | (25.4) | % | 293.2 | 310.1 | (16.9) | (5.4) | % | ||||||||||||||||||||||||||||||||||||||||
| Change in fair value of contingent consideration | — | (29.9) | 29.9 | (100.0) | % | (72.8) | (125.7) | 52.9 | (42.1) | % | ||||||||||||||||||||||||||||||||||||||||
| Acquisition-related amortization | 38.5 | 27.1 | 11.4 | 42.1 | % | 93.1 | 81.4 | 11.7 | 14.4 | % | ||||||||||||||||||||||||||||||||||||||||
| Total operating expenses | $ | 1,089.4 | $ | 1,013.6 | $ | 75.8 | 7.5 | % | $ | 3,219.5 | $ | 2,843.6 | $ | 375.9 | 13.2 | % | ||||||||||||||||||||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | |||||||||||||||||||
| Net gains (losses) from non-consolidated T. Rowe Price investment products | |||||||||||||||||||||||
| Cash and discretionary investments | |||||||||||||||||||||||
| Dividend income | $ | 30.3 | $ | 11.5 | $ | 76.0 | $ | 15.1 | |||||||||||||||
| Market-related gains (losses) and equity in earnings (losses) | 2.2 | (15.2) | 19.1 | (73.2) | |||||||||||||||||||
| Total cash and discretionary investments | 32.5 | (3.7) | 95.1 | (58.1) | |||||||||||||||||||
| Seed capital investments | |||||||||||||||||||||||
| Dividend income | 0.3 | 0.2 | 1.2 | 0.6 | |||||||||||||||||||
| Market-related gains (losses) and equity in earnings (losses) | (4.5) | (14.1) | 25.0 | (77.5) | |||||||||||||||||||
| Net gains recognized upon deconsolidation | 0.7 | — | 0.7 | 6.8 | |||||||||||||||||||
| Investments used to hedge the supplemental savings plan liability | (19.7) | (26.3) | 58.6 | (178.0) | |||||||||||||||||||
| Total net gains (losses) from non-consolidated T. Rowe Price investment products | 9.3 | (43.9) | 180.6 | (306.2) | |||||||||||||||||||
| Other investment income | 21.4 | 2.4 | 33.1 | 4.9 | |||||||||||||||||||
| Net gains (losses) on investments | 30.7 | (41.5) | 213.7 | (301.3) | |||||||||||||||||||
| Net gains (losses) on consolidated sponsored investment portfolios | (24.4) | (41.7) | 45.4 | (247.7) | |||||||||||||||||||
| Other income (losses), including foreign currency losses | (3.5) | 0.4 | (14.7) | (12.2) | |||||||||||||||||||
| Non-operating income (loss) | $ | 2.8 | $ | (82.8) | $ | 244.4 | $ | (561.2) | |||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||
| (in millions) | 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | |||||||||||||||||||
| Operating expenses reflected in net operating income | $ | (1.4) | $ | (1.8) | $ | (8.8) | $ | (6.2) | |||||||||||||||
| Net investment income (loss) reflected in non-operating income | (24.4) | (41.8) | 45.4 | (247.8) | |||||||||||||||||||
| Impact on income before taxes | $ | (25.8) | $ | (43.6) | $ | 36.6 | $ | (254.0) | |||||||||||||||
| Net income (loss) attributable to our interest in the consolidated T. Rowe Price investment products | $ | (11.8) | $ | (17.0) | $ | 25.6 | $ | (122.1) | |||||||||||||||
| Net income (loss) attributable to redeemable non-controlling interests (unrelated third-party investors) | (14.0) | (26.6) | 11.0 | (131.9) | |||||||||||||||||||
| $ | (25.8) | $ | (43.6) | $ | 36.6 | $ | (254.0) | ||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||||||||
| 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | ||||||||||||||||||||
| Statutory U.S. federal income tax rate | 21.0 | % | 21.0 | % | 21.0 | % | 21.0 | % | |||||||||||||||
|
State income taxes for current year, net of federal income tax benefits
(1)
|
3.3 | 3.4 | 3.0 | 3.5 | |||||||||||||||||||
|
Net (income) losses attributable to redeemable non-controlling interests
(2)
|
0.1 | 2.5 | (0.2) | 1.6 | |||||||||||||||||||
| Net excess tax benefits from stock-based compensation plans activity | (0.4) | (0.5) | (0.3) | (0.5) | |||||||||||||||||||
| Other items, including valuation allowances | 0.8 | 0.8 | 2.6 | — | |||||||||||||||||||
| Effective income tax rate | 24.8 | % | 27.2 | % | 26.1 | % | 25.6 | % | |||||||||||||||
|
Three months ended 9/30/2023
|
|||||||||||||||||||||||||||||||||||
| Operating expenses | Net operating income | Non-operating income (loss) |
Provision (benefit) for income taxes
(6)
|
Net income attributable to T. Rowe Price |
Diluted earnings per share
(7)
|
||||||||||||||||||||||||||||||
| U.S. GAAP Basis (FS line item) | $ | 1,089.4 | $ | 581.3 | $ | 2.8 | $ | 144.9 | $ | 453.2 | $ | 1.97 | |||||||||||||||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||||||||
| Acquisition-related non-GAAP adjustments: | |||||||||||||||||||||||||||||||||||
|
Investment and NCI amortization and impairments
(1)
(Capital allocation-based income and Compensation and related costs)
|
10.6 | 15.2 | — | 4.6 | 10.6 | 0.04 | |||||||||||||||||||||||||||||
|
Acquisition-related retention arrangements
(1)
(Compensation and related costs)
|
(13.7) | 13.7 | — | 4.2 | 9.5 | 0.04 | |||||||||||||||||||||||||||||
|
Intangible assets amortization and impairments
(1)
|
(38.5) | 38.5 | — | 11.7 | 26.8 | 0.12 | |||||||||||||||||||||||||||||
| Total acquisition-related non-GAAP adjustments | (41.6) | 67.4 | — | 20.5 | 46.9 | 0.20 | |||||||||||||||||||||||||||||
|
Supplemental savings plan liability
(3)
(Compensation and related costs)
|
14.2 | (14.2) | 19.7 | 1.7 | 3.8 | 0.02 | |||||||||||||||||||||||||||||
|
Consolidated T. Rowe Price investment products
(4)
|
(0.7) | 1.4 | 24.4 | 3.6 | 8.2 | 0.03 | |||||||||||||||||||||||||||||
|
Other non-operating income
(5)
|
— | — | (18.2) | (5.6) | (12.6) | (0.05) | |||||||||||||||||||||||||||||
| Adjusted Non-GAAP Basis | $ | 1,061.3 | $ | 635.9 | $ | 28.7 | $ | 165.1 | $ | 499.5 | $ | 2.17 | |||||||||||||||||||||||
|
Three months ended 9/30/2022
|
|||||||||||||||||||||||||||||||||||
| Operating expenses | Net operating income | Non-operating income (loss) |
Provision (benefit) for income taxes
(6)
|
Net income attributable to T. Rowe Price |
Diluted earnings per share
(7)
|
||||||||||||||||||||||||||||||
| U.S. GAAP Basis (FS line item) | $ | 1,013.6 | $ | 574.6 | $ | (82.8) | $ | 134.0 | $ | 384.4 | $ | 1.66 | |||||||||||||||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||||||||
| Acquisition-related non-GAAP adjustments: | |||||||||||||||||||||||||||||||||||
|
Investment and NCI amortization and impairments
(1)
(Capital allocation-based income and Compensation and related costs)
|
5.6 | 7.6 | — | 1.4 | 6.2 | 0.03 | |||||||||||||||||||||||||||||
|
Acquisition-related retention arrangements
(1)
(Compensation and related costs)
|
(17.1) | 17.1 | — | 3.0 | 14.1 | 0.06 | |||||||||||||||||||||||||||||
|
Contingent consideration
(1)
|
29.9 | (29.9) | — | (3.8) | (26.1) | (0.11) | |||||||||||||||||||||||||||||
|
Intangible assets amortization and impairments
(1)
|
(27.1) | 27.1 | — | 5.1 | 22.0 | 0.09 | |||||||||||||||||||||||||||||
|
Transaction costs
(2)
(General, admin and other)
|
(0.1) | 0.1 | — | — | 0.1 | — | |||||||||||||||||||||||||||||
| Total acquisition-related non-GAAP adjustments | (8.8) | 22.0 | — | 5.7 | 16.3 | 0.07 | |||||||||||||||||||||||||||||
|
Supplemental savings plan liability
(3)
(Compensation and related costs)
|
24.7 | (24.7) | 26.3 | 0.1 | 1.5 | 0.01 | |||||||||||||||||||||||||||||
|
Consolidated T. Rowe Price investment products
(4)
|
(1.3) | 1.8 | 41.7 | (0.3) | 17.2 | 0.07 | |||||||||||||||||||||||||||||
|
Other non-operating income
(5)
|
— | — | 11.1 | (0.1) | 11.2 | 0.05 | |||||||||||||||||||||||||||||
| Adjusted Non-GAAP Basis | $ | 1,028.2 | $ | 573.7 | $ | (3.7) | $ | 139.4 | $ | 430.6 | $ | 1.86 | |||||||||||||||||||||||
|
Nine months ended 9/30/2023
|
|||||||||||||||||||||||||||||||||||
| Operating expenses | Net operating income | Non-operating income (loss) |
Provision (benefit) for income taxes
(6)
|
Net income attributable to T. Rowe Price |
Diluted earnings per share
(7)
|
||||||||||||||||||||||||||||||
| U.S. GAAP Basis (FS line item) | $ | 3,219.5 | $ | 1,599.0 | $ | 244.4 | $ | 481.3 | $ | 1,351.1 | $ | 5.86 | |||||||||||||||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||||||||
| Acquisition-related non-GAAP adjustments: | |||||||||||||||||||||||||||||||||||
|
Investment and NCI amortization and impairments
(1)
(Capital allocation-based income and Compensation and related costs)
|
20.8 | 29.6 | — | 6.2 | 23.4 | 0.10 | |||||||||||||||||||||||||||||
|
Acquisition-related retention arrangements
(1)
(Compensation and related costs)
|
(41.5) | 41.5 | — | 7.2 | 34.3 | 0.15 | |||||||||||||||||||||||||||||
|
Contingent consideration
(1)
|
72.8 | (72.8) | — | (8.0) | (64.8) | (0.28) | |||||||||||||||||||||||||||||
|
Intangible assets amortization and impairments
(1)
|
(93.1) | 93.1 | — | 17.7 | 75.4 | 0.33 | |||||||||||||||||||||||||||||
| Total acquisition-related non-GAAP adjustments | (41.0) | 91.4 | — | 23.1 | 68.3 | 0.30 | |||||||||||||||||||||||||||||
|
Supplemental savings plan liability
(3)
(Compensation and related costs)
|
(61.3) | 61.3 | (58.6) | 1.4 | 1.3 | 0.01 | |||||||||||||||||||||||||||||
|
Consolidated T. Rowe Price investment products
(4)
|
(7.2) | 8.8 | (45.4) | (0.5) | (25.1) | (0.11) | |||||||||||||||||||||||||||||
|
Other non-operating income
(5)
|
— | — | (49.1) | (8.9) | (40.2) | (0.18) | |||||||||||||||||||||||||||||
| Adjusted Non-GAAP Basis | $ | 3,110.0 | $ | 1,760.5 | $ | 91.3 | $ | 496.4 | $ | 1,355.4 | $ | 5.88 | |||||||||||||||||||||||
| Nine months ended 9/30/2022 | |||||||||||||||||||||||||||||||||||
| Operating expenses | Net operating income | Non-operating income (loss) |
Provision (benefit) for income taxes
(6)
|
Net income attributable to T. Rowe Price |
Diluted earnings per share
(7)
|
||||||||||||||||||||||||||||||
| U.S. GAAP Basis (FS line item) | $ | 2,843.6 | $ | 2,120.6 | $ | (561.2) | $ | 399.4 | $ | 1,291.9 | $ | 5.54 | |||||||||||||||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||||||||||||||
| Acquisition-related non-GAAP adjustments: | |||||||||||||||||||||||||||||||||||
|
Investment and NCI amortization and impairments
(1)
(Capital allocation-based income and Compensation and related costs)
|
16.9 | 22.8 | — | 6.5 | 16.3 | 0.07 | |||||||||||||||||||||||||||||
|
Acquisition-related retention arrangements
(1)
(Compensation and related costs)
|
(54.3) | 54.3 | — | 15.4 | 38.9 | 0.17 | |||||||||||||||||||||||||||||
|
Contingent consideration
(1)
|
125.7 | (125.7) | — | (35.7) | (90.0) | (0.40) | |||||||||||||||||||||||||||||
|
Intangible assets amortization and impairments
(1)
|
(81.4) | 81.4 | — | 23.1 | 58.3 | 0.25 | |||||||||||||||||||||||||||||
|
Transaction costs
(2)
(General, admin and other)
|
(0.9) | 0.9 | — | 0.2 | 0.7 | — | |||||||||||||||||||||||||||||
| Total acquisition-related non-GAAP adjustments | 6.0 | 33.7 | — | 9.5 | 24.2 | 0.09 | |||||||||||||||||||||||||||||
|
Supplemental savings plan liability
(3)
(Compensation and related costs)
|
169.2 | (169.2) | 178.0 | 2.5 | 6.3 | 0.03 | |||||||||||||||||||||||||||||
|
Consolidated T. Rowe Price investment products
(4)
|
(4.2) | 6.3 | 247.7 | 34.7 | 87.4 | 0.38 | |||||||||||||||||||||||||||||
|
Other non-operating income
(5)
|
— | — | 77.4 | 22.0 | 55.4 | 0.24 | |||||||||||||||||||||||||||||
| Adjusted Non-GAAP Basis | $ | 3,014.6 | $ | 1,991.4 | $ | (58.1) | $ | 468.1 | $ | 1,465.2 | $ | 6.28 | |||||||||||||||||||||||
| Three months ended | Nine months ended | ||||||||||||||||
| 9/30/2023 | 9/30/2022 | 9/30/2023 | 9/30/2022 | ||||||||||||||
| Adjusted net income attributable to T. Rowe Price | $ | 499.5 | $ | 430.6 | $ | 1,355.4 | $ | 1,465.2 | |||||||||
| Less: adjusted net income allocated to outstanding restricted stock and stock unit holders | 11.7 | 10.7 | 32.8 | 34.1 | |||||||||||||
| Adjusted net income allocated to common stockholders | $ | 487.8 | $ | 419.9 | $ | 1,322.6 | $ | 1,431.1 | |||||||||
| (in millions) | 9/30/2023 | 12/31/2022 | |||||||||
| Cash and cash equivalents | $ | 2,578.7 | $ | 1,755.6 | |||||||
| Discretionary investments | 486.3 | 449.7 | |||||||||
| Total cash and discretionary investments | 3,065.0 | 2,205.3 | |||||||||
| Redeemable seed capital investments | 1,167.4 | 1,120.3 | |||||||||
| Investments used to hedge the supplemental savings plan liability | 783.9 | 760.7 | |||||||||
| Total cash and investments in T. Rowe Price products | $ | 5,016.3 | $ | 4,086.3 | |||||||
| (in millions) | Cash and cash equivalents | Investments |
Net assets of consolidated T. Rowe Price investment products
(1)
|
Total | |||||||||||||||||||
| Cash and discretionary investments | $ | 2,578.7 | $ | 263.0 | $ | 223.3 | $ | 3,065.0 | |||||||||||||||
| Seed capital investments | — | 322.7 | 844.7 | 1,167.4 | |||||||||||||||||||
| Investments used to hedge the supplemental savings plan liability | — | 717.6 | 66.3 | 783.9 | |||||||||||||||||||
| Total cash and investments in T. Rowe Price products attributable to T. Rowe Price | 2,578.7 | 1,303.3 | 1,134.3 | 5,016.3 | |||||||||||||||||||
|
Investments in affiliated private investment funds
(2)
|
— | 825.0 | — | 825.0 | |||||||||||||||||||
| Investments in CLOs | — | 110.1 | — | 110.1 | |||||||||||||||||||
| Investment in UTI and other investments | — | 265.2 | — | 265.2 | |||||||||||||||||||
| Total cash and investments attributable to T. Rowe Price | 2,578.7 | 2,503.6 | 1,134.3 | 6,216.6 | |||||||||||||||||||
| Redeemable non-controlling interests | — | — | 560.2 | 560.2 | |||||||||||||||||||
| As reported on unaudited condensed consolidated balance sheet at September 30, 2023 | $ | 2,578.7 | $ | 2,503.6 | $ | 1,694.5 | $ | 6,776.8 | |||||||||||||||
| (in millions) | Recurring dividend | Special dividend | Stock repurchases | Total cash returned to stockholders | |||||||||||||||||||
| 2021 | $ | 1,003.7 | $ | 699.8 | $ | 1,136.0 | $ | 2,839.5 | |||||||||||||||
| 2022 | 1,108.8 | — | 855.3 | 1,964.1 | |||||||||||||||||||
|
Nine months ended 9/30/2023
|
841.1 | — | 150.6 | 991.7 | |||||||||||||||||||
| Total | $ | 2,953.6 | $ | 699.8 | $ | 2,141.9 | $ | 5,795.3 | |||||||||||||||
| Nine months ended | |||||||||||||||||||||||||||||||||||||||||||||||
| 9/30/2023 | 9/30/2022 | ||||||||||||||||||||||||||||||||||||||||||||||
|
(in millions)
|
Cash flow attributable to T. Rowe Price | Cash flow attributable to consolidated sponsored investment products |
Elims
|
As reported
|
Cash flow attributable to T. Rowe Price | Cash flow attributable to consolidated sponsored investment products |
Elims
|
As reported
|
|||||||||||||||||||||||||||||||||||||||
| Cash flows from operating activities | |||||||||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 1,351.1 | $ | 36.6 | $ | (25.6) | $ | 1,362.1 | $ | 1,291.9 | $ | (254.0) | $ | 122.1 | $ | 1,160.0 | |||||||||||||||||||||||||||||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities | |||||||||||||||||||||||||||||||||||||||||||||||
| Depreciation, amortization and impairments of property, equipment and software | 181.6 | — | — | 181.6 | 166.0 | — | — | 166.0 | |||||||||||||||||||||||||||||||||||||||
| Amortization and impairment of acquisition-related assets and retention agreements | 165.6 | — | — | 165.6 | 158.4 | — | — | 158.4 | |||||||||||||||||||||||||||||||||||||||
| Fair value remeasurement of contingent liability | (72.8) | — | — | (72.8) | (125.7) | — | — | (125.7) | |||||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | 169.7 | — | — | 169.7 | 185.7 | — | — | 185.7 | |||||||||||||||||||||||||||||||||||||||
| Net (gains) losses recognized on investments | (326.0) | — | 25.6 | (300.4) | 506.6 | — | (122.1) | 384.5 | |||||||||||||||||||||||||||||||||||||||
| Net redemptions in sponsored investment products used to economically hedge supplemental savings plan liability | 101.3 | — | — | 101.3 | 33.8 | — | — | 33.8 | |||||||||||||||||||||||||||||||||||||||
| Net change in trading securities held by consolidated sponsored investment products | — | (779.9) | — | (779.9) | — | 291.0 | — | 291.0 | |||||||||||||||||||||||||||||||||||||||
| Other changes | 546.8 | 11.8 | (9.3) | 549.3 | 236.1 | 21.0 | (16.2) | 240.9 | |||||||||||||||||||||||||||||||||||||||
| Net cash provided by (used in) operating activities | 2,117.3 | (731.5) | (9.3) | 1,376.5 | 2,452.8 | 58.0 | (16.2) | 2,494.6 | |||||||||||||||||||||||||||||||||||||||
| Net cash provided by (used in) investing activities | (333.3) | (35.6) | 407.0 | 38.1 | (54.7) | (8.7) | (6.1) | (69.5) | |||||||||||||||||||||||||||||||||||||||
| Net cash provided by (used in) financing activities | (960.9) | 741.4 | (397.7) | (617.2) | (1,554.9) | (84.1) | 22.3 | (1,616.7) | |||||||||||||||||||||||||||||||||||||||
| Effect of exchange rate changes on cash and cash equivalents of consolidated sponsored investment products | — | (1.8) | — | (1.8) | — | 11.8 | — | 11.8 | |||||||||||||||||||||||||||||||||||||||
| Net change in cash and cash equivalents during period | 823.1 | (27.5) | — | 795.6 | 843.2 | (23.0) | — | 820.2 | |||||||||||||||||||||||||||||||||||||||
| Cash and cash equivalents at beginning of year | 1,755.6 | 119.1 | — | 1,874.7 | 1,523.1 | 101.1 | — | 1,624.2 | |||||||||||||||||||||||||||||||||||||||
| Cash and cash equivalents at end of period | $ | 2,578.7 | $ | 91.6 | $ | — | $ | 2,670.3 | $ | 2,366.3 | $ | 78.1 | $ | — | $ | 2,444.4 | |||||||||||||||||||||||||||||||
| Month |
Total Number of
Shares Purchased
|
Average Price
Paid per Share
|
Total Number of
Shares Purchased as
Part of Publicly
Announced Program
|
Maximum Number of Shares that May Yet Be Purchased Under the Program | ||||||||||||||||||||||
| July | 24,840 | $ | 118.88 | — | 8,354,638 | |||||||||||||||||||||
| August | 314,929 | $ | 112.14 | 304,011 | 8,050,627 | |||||||||||||||||||||
| September | 687,082 | $ | 106.22 | 673,247 | 7,377,380 | |||||||||||||||||||||
| Total | 1,026,851 | $ | 108.34 | 977,258 | ||||||||||||||||||||||
| Authorization Dates | 7/1/2023 |
Total Number of
Shares Purchased |
Maximum Number of Shares that May Yet Be Purchased at 9/30/2023
|
|||||||||||||||||||||||
| March 2020 | 8,354,638 | (977,258) | 7,377,380 | |||||||||||||||||||||||
| 3(i) | |||||||||||
| 3(ii) | |||||||||||
| 10.01 |
T. Rowe Price, Inc. 1986 Employee Stock Purchase Plan, Restated as of April 26, 2017, as amended.
(Incorporated by reference from Form S-8 registration statement filed on August 2, 2023.)
|
||||||||||
| 10.02 | |||||||||||
| 15 | |||||||||||
| 31(i).1 | |||||||||||
| 31(i).2 | |||||||||||
| 32 | |||||||||||
| 101 | The following series of unaudited XBRL-formatted documents are collectively included herewith as Exhibit 101. The financial information is extracted from T. Rowe Price Group’s unaudited condensed consolidated interim financial statements and notes that are included in this Form 10-Q Report. | ||||||||||
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ||||||||||
| 101.SCH | XBRL Taxonomy Extension Schema Document | ||||||||||
| 101.CAL | XBRL Taxonomy Calculation Linkbase Document | ||||||||||
| 101.LAB | XBRL Taxonomy Label Linkbase Document | ||||||||||
| 101.PRE | XBRL Taxonomy Presentation Linkbase Document | ||||||||||
| 101.DEF | XBRL Taxonomy Definition Linkbase Document | ||||||||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|